SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho, J Zhang… - Nature, 2011 - nature.com
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …
被引用次数：548 相关文章

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho, J Zhang… - …, 2011 - scholars.northwestern.edu
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho, J Zhang… - Nature, 2011 - profiles.wustl.edu
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho, J Zhang… - Nature, 2011 - europepmc.org
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

Z Ding, CJ Wii, GC Chu, Y Xiao, D Ho, J Zhang… - Nature, 2011 - go.gale.com
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho… - …, 2011 - utsouthwestern.elsevierpure.com
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho, J Zhang… - …, 2011 - search.ebscohost.com
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

ZH Ding, CJ Wu, GC Chu, YH Xiao, D Ho, JF Zhang… - Nature, 2011 - repository.cshl.edu
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho, J Zhang… - Nature, 2011 - ideas.repec.org
Four-gene marker in prostate cancer Using a Smad4/Pten null transgenic mouse model of
prostate cancer, Ding et al. show that the transforming growth factor-β (TGFβ) signalling …

[引用][C] SMAD4―dependent barrier constrains prostate cancer growth and metastatic progression

Z DING, CJ WU, Y HOSHIDA, D HILLER… - Nature …, 2011 - pascal-francis.inist.fr
Author ZHIHU DING 1 2 3 4; WU, Chang-Jiun 1 2 3 4; HOSHIDA, Yujin 8 9; HILLER, David
10; BAOLI HU 1 2; SHAN JIANG 1 2; HONGWU ZHENG 1 2 3 4; STEGH, Alexander H 1 2 3 …